Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Shield Therapeutics PLC (GB:STX)
LSE:STX
RESEARCH TOOLSreports
Holding GB:STX?
Track your performance easily
STX Stock Chart & Stats
Day’s Range― - ―
52-Week Range1.06p - 7.70p
Previous CloseN/A
Volume699.61K
Average Volume (3M)1.51M
Market Cap
£26.04M
Enterprise Value23.86M
Total Cash (Recent Filing)$20.98M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Apr 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,041,690,400
10 Day Avg. Volume1,303,758
30 Day Avg. Volume1,509,421
Standard Deviation0.28
R-Squared0.05
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.40
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.60
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Shield Therapeutics News
PremiumCompany Announcements
Shield Therapeutics Secures $10 Million Funding and Expands Share Capital
PremiumCompany Announcements
Shield Therapeutics Raises Funds through RetailBook Offer
PremiumCompany Announcements
Shield Therapeutics Announces New RetailBook Share Offer
PremiumCompany Announcements
Shield Therapeutics Aims for Financial Boost through Share SubscriptionPremiumCompany Announcements
Shield Therapeutics Reports Strong ACCRUFeR® Sales and Study Progress
PremiumCompany Announcements
Shield Therapeutics Sees Revenue Surge and Financial BoostPremiumCompany Announcements
Shield Therapeutics’ Pediatric IDA Trial Succeeds
PremiumCompany Announcements
Shield Therapeutics Sees Strong Revenue GrowthSTX FAQ
What was Shield Therapeutics PLC’s price range in the past 12 months?
Shield Therapeutics PLC lowest share price was 1.06p and its highest was 7.70p in the past 12 months.
What is Shield Therapeutics PLC’s market cap?
Shield Therapeutics PLC’s market cap is £26.04M.
When is Shield Therapeutics PLC’s upcoming earnings report date?
Shield Therapeutics PLC’s upcoming earnings report date is Apr 24, 2025 which is in 100 days.
How were Shield Therapeutics PLC’s earnings last quarter?
Shield Therapeutics PLC released its earnings results on Sep 04, 2024. The company reported -0.016p earnings per share for the quarter, missing the consensus estimate of N/A by -0.016p.
Is Shield Therapeutics PLC overvalued?
According to Wall Street analysts Shield Therapeutics PLC’s price is currently Overvalued.
Does Shield Therapeutics PLC pay dividends?
Shield Therapeutics PLC does not currently pay dividends.
What is Shield Therapeutics PLC’s EPS estimate?
Shield Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shield Therapeutics PLC have?
Shield Therapeutics PLC has 1,041,690,400 shares outstanding.
What happened to Shield Therapeutics PLC’s price movement after its last earnings report?
Shield Therapeutics PLC reported an EPS of -0.016p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -15.094%.
Which hedge fund is a major shareholder of Shield Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:STX
---
Company Description
Shield Therapeutics PLC
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments which is based on key products include Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. It generates maximum revenue from Feraccru segment.
---
Technical Analysis
---